MYnd Analytics Inc (NASDAQ:MYND)’s stock price shot up 7.4% on Monday . The company traded as high as $1.65 and last traded at $1.60, 163,069 shares changed hands during trading. A decline of 11% from the average session volume of 182,738 shares. The stock had previously closed at $1.49.
A number of research firms have weighed in on MYND. Maxim Group set a $4.00 price objective on shares of MYnd Analytics and gave the stock a “buy” rating in a research report on Friday. ValuEngine upgraded shares of Valmont Industries from a “sell” rating to a “hold” rating in a research report on Friday. Finally, Dawson James reiterated a “buy” rating on shares of Adial Pharmaceuticals in a research report on Friday, April 12th.
The firm’s 50-day moving average price is $1.34. The firm has a market cap of $15.17 million, a price-to-earnings ratio of -0.86 and a beta of 2.92. The company has a debt-to-equity ratio of 1.19, a current ratio of 0.81 and a quick ratio of 0.81.
MYnd Analytics (NASDAQ:MYND) last issued its earnings results on Friday, May 10th. The company reported ($0.27) EPS for the quarter. The business had revenue of $0.46 million during the quarter. MYnd Analytics had a negative net margin of 561.61% and a negative return on equity of 467.46%. Equities research analysts predict that MYnd Analytics Inc will post -1.13 EPS for the current year.
In other MYnd Analytics news, Director John Pappajohn bought 200,000 shares of MYnd Analytics stock in a transaction dated Thursday, May 23rd. The stock was acquired at an average cost of $1.25 per share, for a total transaction of $250,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 36.88% of the stock is owned by corporate insiders.
MYnd Analytics Company Profile (NASDAQ:MYND)
MYnd Analytics, Inc operates as a predictive analytics company primarily in the United States. The company manages the delivery of telepsychiatry and telebehavioral health services through a network of psychiatrists, psychologists, and therapists. The company is commercializing its psychiatric electroencephalogram (EEG) evaluation registry predictive analytics tool to help physicians reduce trial and error treatment in mental health.
Read More: Are all No-Load Funds Equal?
Receive News & Ratings for MYnd Analytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYnd Analytics and related companies with MarketBeat.com's FREE daily email newsletter.